Coherus’ Q2 2023 Financial Results Show Quadrupling of Cimerli® (Ranibizumab) Sales Since Last Quarter

Aug 2, 2023

Coherus BioSciences announced its Q2 2023 financial results, reporting that sales of its Cimerli® (ranibizumab), biosimilar to Genentech’s Lucentis®, has quadrupled to $26.7M since the last quarter.  It also reported that its net revenue has risen 81% compared to the previous quarter.  Yumisry®, Coherus’s biosimilar to AbbVie’s Humira® (adalimumab) was launched in the US on 3 July.

Print Page Mail Article